Ipamorelin.
About Ipamorelin
Ipamorelin is among the peptides researched in the context of the growth hormone (GH) axis. Ipamorelin selectively activates the ghrelin receptor (GHS-R1a) to trigger pulsatile growth hormone release, without showing significant effects on cortisol or prolactin in studies.
Research Application
Studied in GH-axis research for its high receptor selectivity — without the cortisol or prolactin increases described for older GH secretagogues. The only known clinical trial (post-operative ileus) did not meet its primary endpoint.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
Numerous preclinical and some clinical studies exist on the GH axis, with evidentiary strength varying by substance.
- Raun K, et al. Eur J Endocrinol. 1998;139(5):552–561. PMID 9849822
- Gobburu JV, et al. Pharm Res. 1999;16(9):1412–1416. PMID 10496658
- Andersen NB, et al. Growth Horm IGF Res. 2001;11(5):266–272. PMID 11735244
- Beck DE, et al. Int J Colorectal Dis. 2014;29(12):1527–1534. PMID 25331030
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Question about Ipamorelin?
We reply personally – via email or Telegram.